Investor Cathie Wood, a long-time Tesla bull known for first investing in the company a decade ago at $13 per share, condemned the growing resistance to Tesla CEO Elon Musk’s potential $1 trillion pay package. Over the weekend, the ARK Invest…
Category: 6. Business
-
Gilead to spotlight new virology data across HIV, viral hepatitis and respiratory diseases at IDWeek 2025
– Additional Phase 3 PURPOSE data reinforce the safety profile of twice-yearly Yeztugo® as an effective HIV prevention option across diverse populations –
– New data show higher treatment satisfaction after switching from IM CAB+RPV to…
Continue Reading
-
SAVR Bests TAVI in Patients With Highly Calcific Aortic Valves
The results underscore the need to perform CT imaging when deciding between procedures in patients with aortic stenosis.
COPENHAGEN, Denmark—Among patients with severe aortic stenosis at low- or intermediate-risk for surgery who also…
Continue Reading
-
Global Fund welcomes renewed commitment from GSK and ViiV Healthcare to expand community-led health solutions with £6 million joint pledge ahead of 8th Replenishment
LONDON/GENEVA – The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) today welcomed a new £6 million investment by GSK plc (LSE/NYSE: GSK) and ViiV Healthcare, the global specialist HIV company majority owned by GSK, with…
Continue Reading
-
CheckMate 8HW Data Further Support Nivolumab/Ipilimumab as a SOC Option in First-line MSI-H/dMMR mCRC
The addition of ipilimumab (Yervoy) to nivolumab (Opdivo) continued to demonstrate clinically meaningful progression-free survival (PFS) improvement over nivolumab monotherapy with no new safety signals observed among patients with…
Continue Reading
-
FDA Approves Third-Ever Drug for Lupus Nephritis – Medscape
- FDA Approves Third-Ever Drug for Lupus Nephritis Medscape
- Roche Receives FDA Approval for Kidney Inflammation Drug The Wall Street Journal
- FDA Approves Gazyva® (obinutuzumab) for the Treatment of Adults with Lupus Nephritis PR Newswire
- FDA…
Continue Reading
-
New 5-year data show Biktarvy is effective, improves QoL in people with HIV
The combination HIV treatment bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF; Biktarvy, Gilead) continues to be effective and well-tolerated five years after starting the regimen, according to new data from the BICSTaR trial presented at…
Continue Reading
-
Cancer Vaccine/Pembrolizumab Improves PFS in Treatment-Naive Melanoma
IO102-IO103, a cancer vaccine, plus pembrolizumab (Keytruda) yieleded a clinically menaingful improvement in median progression-free survival (PFS) vs pembrolizumab alone in patients with treatment-naïve advanced melanoma, according to results…
Continue Reading
-
Journal of Medical Internet Research
Introduction
Secondary prevention of coronary heart disease (CHD) aims to prevent recurrent coronary events following a clinical diagnosis [,]. High adherence to secondary prevention interventions, particularly aggressive lifestyle modifications…
Continue Reading
